10:32 AM EDT, 05/12/2025 (MT Newswires) -- Esperion Therapeutics ( ESPR ) said Monday it reached a settlement with Micro Labs USA and its affiliate, Micro Labs, resolving a patent dispute over a proposed generic version of its cholesterol-lowering drug, Nexletol.

Under the terms of the agreement, Micro Labs agreed not to market a generic version of Nexletol in the US before April 19, 2040, except under limited circumstances typically included in such settlements.

Esperion said the litigation it filed against Micro Labs has now been resolved. However, patent lawsuits against several other generic drugmakers, including Accord Healthcare, Alkem Laboratories, Aurobindo Pharma, Dr. Reddy's Laboratories (RDY), Hetero USA, MSN Pharmaceuticals, Renata, and Sandoz, remain ongoing.